Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1Dermatologic 1

Conditions

Lymphoma 2Subcutaneous panniculitis-like T-cell lymphoma 1Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Extranodal NK-T-Cell 1Leukemia 1

Interventions

Cyclophosphamide 211Rituximab 193fludarabine 134fludarabine phosphate 91Vincristine 78Cytarabine 66Etoposide 65Doxorubicin 61Dexamethasone 60Lenalidomide 59venetoclax 56ibrutinib 55Prednisone 54Bendamustine Hydrochloride 51obinutuzumab 48Filgrastim 46Bortezomib 46Specimen Handling 42pembrolizumab 39Gemcitabine 39Methotrexate 38Melphalan 38Biopsy 38Peripheral Blood Stem Cell Transplantation 32Magnetic Resonance Spectroscopy 32Azacitidine 31Vorinostat 29Nivolumab 29Calcium Dobesilate 29Clofarabine 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × siplizumab × Lymphoid × Clear all
NCT01445535 2021-11-03

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
15 enrolled 18 charts
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

NCT00105313 2007-06-14

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

MedImmune LLC

Phase 1 Terminated
80 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡